JW (Cayman) Therapeutics (HKG:2126) granted a total of 387,740 share options and 77,548 restricted share units (RSU) to two grantees on Monday, a same-day bourse filing said.
The options and RSUs were granted under the drugmaker's post-IPO incentivization and restricted share unit schemes.
Each option entitles the grantees, which are employees of the firm, to subscribe for one share at HK$1.36 apiece starting Jan. 6, 2025, and ending Jan. 5, 2035.
Each RSU, which is valid between Jan. 6, 2025, and Jan. 5, 2035, also allows the grantees to receive one share subject to vesting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.